Detailed Narrative
Cystic Fibrosis Leadership and Innovation
Vertex continues to expand its leadership in cystic fibrosis with ALYFTREK, its fifth approved CFTR modulator, demonstrating superior protein function restoration and once-daily dosing. Recent Phase III results in 2- to 5-year-olds showed a significant 9.6 millimoles mean reduction in sweat chloride from a TRIKAFTA baseline, with 65% of patients achieving normal levels. The company is also advancing next-gen 3.0 modulators like VX-828 and VX-581, and VX-522 for the 5,000 patients who do not produce CFTR protein, with a Phase I/II readout expected in H2 2026.
Emerging Renal Franchise as a Growth Vertical
The renal pipeline is positioned as Vertex's fourth vertical, with povetacicept (pove) leading the way for IgA nephropathy (IgAN), membranous nephropathy, and generalized myasthenia gravis (gMG). Pove, a dual BAFF APRIL inhibitor, is designed for once-monthly subcutaneous administration via auto-injector, offering potential best-in-class efficacy and convenience. The company initiated rolling BLA submission for IgAN in December 2025 and expects to complete it in H1 2026, with Phase II/III studies for membranous and gMG also progressing.
CASGEVY and JOURNAVX Commercial Momentum
CASGEVY, for sickle cell disease and beta thalassemia, showed strong momentum in Q4 FY25 with 111 new patient initiations and 30 infusions, contributing $54 million in quarterly revenue. Reimbursement access is expanding, with over 90% access for Medicaid and commercial patients in the U.S. and coverage secured in key European countries. JOURNAVX, for acute pain, achieved 550,000 prescriptions in FY25, with a 50-50 split between hospital and retail channels, and broad payer access established. The company plans to double its field force and expects to more than triple prescriptions in 2026.
Inaxaplin and VX-407 Progress in Kidney Diseases
Inaxaplin, for APOL1-mediated kidney disease (AMKD), completed enrollment in the interim analysis cohort of the AMPLITUDE pivotal study. Results from this cohort are expected late 2026 or early 2027, potentially leading to a U.S. accelerated approval filing. The AMPLIFIED study for AMKD patients with moderate proteinuria or type 2 diabetes is expected to yield results in mid-2026. Additionally, VX-407, targeting autosomal dominant polycystic kidney disease (ADPKD), is enrolling patients in its Phase II proof-of-concept study, with enrollment completion expected in 2026.
Strategic Investments and Financial Strength
Vertex's disciplined approach to investment is evident in its Q4 FY25 combined non-GAAP R&D, acquired IPR&D, and SG&A expenses totaling $1.4 billion, reflecting strategic investments in product launches and late-stage pipeline programs. The company maintains a robust financial foundation with $12.3 billion in cash, cash equivalents, and marketable securities at year-end 2025, supporting both internal and external innovation. Share repurchase activity increased in 2025, with approximately 4.8 million shares bought for $2 billion.